摘要：
Multi-drug resistance (MDR) is characterized by the resistance of tumor cells to some antitumor drugs with different structures and mechanisms after the use of a single chemotherapy drug or even the first use of the drug. Notably, MDR has become the largest obstacle to the success of gastric cancer chemotherapies. Non-coding RNAs are defined as a class of RNAs that do not have the ability to code proteins. They are widely involved in important biological functions in life activities. Multiple lines of evidence demonstrated that ncRNAs are closely related to human cancers, including gastric cancer. However, the relationship between ncRNAs and MDR in gastric cancer has been reported, yet the mechanisms are not fully clarified. Therefore, in this review, we systematically summarized the detailed molecular mechanisms of lncRNAs (long noncoding RNAs) and miRNAs (microRNAs) associated with MDR in gastric cancer. Additionally, we speculate that the abnormal expression of ncRNAs is likely to be a novel potential therapeutic target reversing MDR for gastric cancer. Future therapeutics for gastric cancer will most likely be based on noncoding RNAs (ncRNAs) that regulate MDR-related genes.
作者机构：
[Tan, Yan; Tang, Mei-Lun; Chen, Li-Mei; Mi, Peng-Bing; Yu, Zhi-Xing; Zheng, Xing] Univ South China, Prov Cooperat Innovat Ctr Mol Target New Drug Stu, Grp Lead Compound, Dept Pharm,Hunan Prov Key Lab Tumor Microenvironm, Hengyang 421001, Hunan, Peoples R China.;[Lang, Jia-Jia] Univ South China, Hengyang Med Sch, Lab Prot Struct & Funct, Hengyang 421001, Hunan, Peoples R China.
通讯机构：
[Dr. Peng-Bing Mi; Prof. Xing Zheng] G;Group of Lead Compound, Department of Pharmacy, Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, Hunan, Province Cooperative Innovation Center for Molecular Target New Drug Study, University of South China, Hengyang, Hunan, 421001 China
作者机构：
[Zhu, Yanli] Hunan Univ Technol & Business, Sch Resources & Environm, Changsha 410205, Peoples R China.;[Zhou, Jiecan; Xie, Haitao; Fu, Chengxiao] Univ South China, Affiliated Hosp 1, Hengyang Med Sch, Dept Clin Lab,Hengyang Clin Pharmacol Res Ctr, Hengyang 421001, Peoples R China.;[Liu, Hailing] Wuhan Univ, Dept Respirator y & Crit Care Med, Renmin Hosp, Wuhan 430060, Peoples R China.;[Wang, Jikai; Sun, Yiyang; Zeng, Pengfei] Univ South China, Hunan Prov Cooperat Innovat Ctr Mol Target New Dru, Inst Pharm & Pharmacol, Hengyang Med Sch, Hengyang 421001, Hunan, Peoples R China.
通讯机构：
[Jikai Wang] H;Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Institute of Pharmacy & Pharmacology, Hengyang Medical School, University of South China, Hengyang, Hunan 421001, P. R. China
通讯机构：
[Linxi Chen; Lanfang Li] I;Institute of Pharmacy and Pharmacology, Hunan Provincial Key Laboratory of tumor microenvironment responsive drug research, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, College of Basic Medical Science, Hengyang Medical School, University of South China, Hengyang 421001, Hunan, China
摘要：
Apelin is an endogenous ligand of the G protein-coupled receptor APJ. Both apelin and APJ receptors, which are expressed in vascular smooth muscle cells (VSMCs), play important roles in the cardiovascular system. Our previous studies researches indicated that mitophagy mediated apelin-13-induced VSMCs proliferation. How -ever, little is known about how apelin-13 regulates mitophagy to participate in VSMC proliferation. The results of the present study demonstrated that mitochondrial calcium uniporter (MCU) uptake-dependent mitochondrial calcium-induced mitophagy is involved in apelin-13-induced VSMCs proliferation. Apelin-13 promoted the expression of MCU which increases mitochondrial calcium uptake. Apelin-13-induced MCU-dependent mito-chondrial calcium uptake further increased mitochondrial ROS (mtROS) concentrations and promoted mitoph-agy, which can be evidenced through the upregulation of the Dynamin-related protein 1(Drp1), PTEN-induced kinase 1 (PINK1), and Parkin. The clearance of mtROS by Mito-TEMPO significantly reversed apelin-13-induced mitophagy. Moreover, both the Drp1 inhibitor mdivi-1 and siRNA-Drp1 inhibited apelin-13-induced mitophagy. Furthermore, the APJ receptor antagonist F13A, MCU inhibitor Ru360, mitochondria-targeted antioxidant Mito-TEMPO, Drp1 inhibitor Mdivi-1, siRNA-Drp1, siRNA-PINK1, and siRNA-Parkin inhibited the proliferation of VSMCs induced by apelin-13. In ApoE(-/-) mice, intraperitoneal administration of apelin-13 induced the expression of MCU, Drp1, PINK1, Parkin, and alpha-SMA and increased atherosclerotic plaque lesions. However, F13A and Ru360 decreased the expression of MCU, Drp1, PINK1, Parkin, and alpha-SMA and reduced atherosclerotic plaque lesions in ApoE(-/-& nbsp;)mice injected with apelin-13. Collectively, our results demonstrate that MCU-dependent mitochondrial calcium uptake-induced mitophagy is involved in apelin-13-stimulated VSMCs proliferation.
期刊：
Journal of Controlled Release,2022年345:278-291 ISSN：0168-3659
通讯作者：
Cui-Yun Yu
作者机构：
[Wei, Hua; Ma, Wei; Sun, Lu; Meng, Chao; Kang, Gui-Ying] Lanzhou Univ, Coll Chem & Chem Engn, State Key Lab Appl Organ Chem, Lanzhou 730000, Gansu, Peoples R China.;[Wei, Hua; Liu, Ying; Zheng, Zhi; Wang, Dun; Jiang, Ming-Chao; Yu, Cui-Yun] Univ South China, Hunan Prov Cooperat Innovat Ctr Mol Target New Dr, Dept Pharm & Pharmacol, Hengyang 421001, Hunan, Peoples R China.;[Pun, Suzie H.] Univ Washington, Mol Engn & Sci Inst, Dept Bioengn, Seattle, WA 98195 USA.
通讯机构：
[Cui-Yun Yu] H;Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Department of Pharmacy and Pharmacology, University of South China, Hengyang, Hunan 421001, PR China
关键词：
Multicyclic copolymers;Number of cyclic units;Colloidal stability;Enhanced drug delivery
期刊：
Journal of Immunology Research,2022年2022 ISSN：2314-8861
通讯作者：
Tang, SS
作者机构：
[Tang, Sheng-song; Tang, SS; Yang, Ling] Univ South China, Hunan Prov Key Lab Tumor Microenvironm Respons Dr, Hengyang 421001, Peoples R China.;[Tang, Sheng-song; Tang, SS; Yang, Ling] Univ South China, Inst Pharm & Pharmacol, Hengyang 421001, Peoples R China.;[Tang, Sheng-song; Yang, Ling; Ning, Qian] Hunan Univ Med, Sch Pharmaceut Sci, Hunan Prov Key Lab Antibody Based Drug & Intellig, Huaihua 418000, Peoples R China.;[Yang, Ling] First Peoples Hosp Huaihua City, Dept Pharm, Huaihua 418000, Peoples R China.;[Tang, Sheng-song; Tang, SS; Ning, Qian] Hunan Agr Univ, Coll Biosci & Biotechnol, Changsha 410000, Peoples R China.
通讯机构：
[Tang, SS ] U;Univ South China, Hunan Prov Key Lab Tumor Microenvironm Respons Dr, Hengyang 421001, Peoples R China.;Univ South China, Inst Pharm & Pharmacol, Hengyang 421001, Peoples R China.;Hunan Agr Univ, Coll Biosci & Biotechnol, Changsha 410000, Peoples R China.
摘要：
With the huge therapeutic potential, cancer immunotherapy is expected to become the mainstream of cancer treatment. In the current field of cancer immunotherapy, there are mainly five types. Immune checkpoint blockade therapy is one of the most promising directions. Adoptive cell therapy is an important component of cancer immunotherapy. The therapy with the cancer vaccine is promising cancer immunotherapy capable of cancer prevention. Cytokine therapy is one of the pillars of cancer immunotherapy. Oncolytic immunotherapy is a promising novel component of cancer immunotherapy, which with significantly lower incidence of serious adverse reactions. The recent positive results of many clinical trials with cancer immunotherapy may herald good clinical prospects. But there are still many challenges in the broad implementation of immunotherapy. Such as the immunotherapy cannot act on all tumors, and it has serious adverse effects including but not limited to nonspecific and autoimmunity inflammation. Here, we center on recent progress made within the last 5 years in cancer immunotherapy. And we discuss the theoretical background, as well as the opportunities and challenges of cancer immunotherapy.
作者机构：
[Zhou, Chen] Univ South China, Affiliated Nanhua Hosp, Hengyang Med Sch, Dept Pharm, Hengyang 421001, Hunan, Peoples R China.;[Zou, Xiangman; Guo, Zifen; Zhou, Chen; Wen, Xiaosha] Univ South China, Inst Pharm & Pharmacol, Hunan Prov Cooperat Innovat Ctr Mol Target New Dru, Hunan Prov Key Lab Tumor Microenvironm Respons Dru, Hengyang 421001, Peoples R China.
通讯机构：
[Zifen Guo] A;Affiliation Institute of Pharmacy and Pharmacology, Hunan Province Cooperative Innovation Center for Molecular Target New Drugs Study, Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, University of South China, Hengyang, 421001, China
关键词：
Cancers and neoplasms;Cancer risk factors;Metaanalysis;Progesterone;Alu elements;Breast cancer;Genetic dominance;Alleles
摘要：
AIMS: The progesterone response of the nuclear progesterone receptor plays an important role in the female reproductive system. Changes in the function of the progesterone receptor gene may increase the risk of reproductive cancer. The present study performed a meta-analysis to examine whether the progesterone receptor gene PROGINS polymorphism was a susceptibility factor for female reproductive cancer. MATERIALS AND METHODS: We searched the PubMed, Cochrane Library, Web of Science and EMBASE databases for literature on PROGINS polymorphisms and female reproductive cancer published before September 2020. We evaluated the risk using odds ratios [ORs] and 95% confidence intervals via fixed effects models and random-effects models, which were calculated for all five genetic models. We grouped the analyses by race, cancer, and HWE. RESULTS: Thirty studies comprised of 25405 controls and 19253 female reproductive cancer cases were included in this meta-analysis. We observed that the Alu insertion polymorphism and the V660L polymorphism were significantly associated with female reproductive cancer in the allele and dominant genetic models. The allele genetic model and (Alu-insertion polymorphism: OR = 1.22, 95% CI = 1.02-1.45; V660L polymorphism: OR = 1.02, 95% CI = 1.00-1.13) dominant genetic model (Alu-insertion polymorphism: OR = 1.27, 95% CI = 1.03-1.58; V660L polymorphism: OR = 1.10, 95% CI = 1.011.19) demonstrated a significantly increased risk of female reproductive cancer. A subgroup analysis according to ethnicity found that the Alu insertion was associated with female reproductive cancer incidence in white (Allele model: OR = 1.21, 95% CI = 1.00-1.45; Heterozygous model: OR = 3.44, 95% CI = 1.30-9.09) and Asian (Dominant model: OR = 3.12, 95% CI = 1.25-7.79) populations, but the association disappeared for African and mixed racial groups. However, the V660L polymorphism was significantly associated with female reproductive cancer in the African (Allele model: OR = 2.52, 95% CI = 1.14-5.56; Heterozygous model: OR = 2.83, 95% CI = 1.26-6.35) and mixed racial groups (Dominant model: OR = 1.28, 95% CI = 1.01-1.62). Subgroup analysis by cancer showed that the PROGINS polymorphism increased the risk of cancer in the allele model, dominant mode and heterozygous model, but the confidence interval for this result spanned 1 and was not statistically significant. This sensitivity was verified in studies with HWE greater than 0.5. CONCLUSION: Our meta-analysis showed that the progesterone receptor gene Alu insertion and the V660L polymorphism contained in the PROGINS polymorphism were susceptibility factors for female reproductive cancer.
作者机构：
[Zhang, Miao; Wei, Hua; Ma, Liwei; Liu, Fangjun] Lanzhou Univ, Key Lab Nonferrous Met Chem & Resources Utilizat, State Key Lab Appl Organ Chem, Lanzhou 730000, Gansu, Peoples R China.;[Zhang, Miao; Wei, Hua; Ma, Liwei; Liu, Fangjun] Lanzhou Univ, Coll Chem & Chem Engn, Lanzhou 730000, Gansu, Peoples R China.;[Wei, Hua; Wang, Dun; Yu, Cui-Yun] Univ South China, Hunan Prov Cooperat Innovat Ctr Mol Target New Dr, Hengyang 421001, Peoples R China.;[Wei, Hua; Wang, Dun; Yu, Cui-Yun] Univ South China, Dept Pharm & Pharmacol, Hengyang 421001, Peoples R China.
通讯机构：
[Liwei Ma; Hua Wei] S;[Cui-Yun Yu] H;State Key Laboratory of Applied Organic Chemistry, Key Laboratory of Nonferrous Metal Chemistry and Resources Utilization of Gansu Province, and College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, Gansu 730000, China<&wdkj&>Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study & Department of Pharmacy and Pharmacology, University of South China, Hengyang, 421001, China<&wdkj&>State Key Laboratory of Applied Organic Chemistry, Key Laboratory of Nonferrous Metal Chemistry and Resources Utilization of Gansu Province, and College of Chemistry and Chemical Engineering, Lanzhou University, Lanzhou, Gansu 730000, China<&wdkj&>Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study & Department of Pharmacy and Pharmacology, University of South China, Hengyang, 421001, China
关键词：
Anticancer drug delivery;Cell imaging;Conjugated bottlebrush copolymers;Enzyme-responsive;Theranostic micelles
期刊：
Cell Communication and Signaling,2022年20(1):1-14 ISSN：1478-811X
通讯作者：
Lu, B;Chen, Q
作者机构：
[Gong, Shiwei; Jin, Qiumei; Lu, Junwan; Lu, Xiaoang; Lu, Bin; Wang, Jiaxin; Li, Yujie] Wenzhou Med Univ, Sch Lab Med & Life Sci, Prot Qual Control & Dis Lab, Wenzhou 325035, Zhejiang, Peoples R China.;[Gong, Shiwei] Wuhan Pulm Hosp, Wuhan Inst TB Control, Dept Lab Med, Wuhan 430030, Hubei, Peoples R China.;[Lu, Bin] Univ South China, Hengyang Med Sch, Sch Basic Med Sci, Dept Biochem & Mol Biol, Hengyang 421001, Hunan, Peoples R China.;[Chen, Qin] Wenzhou Med Univ, Dept Intens Care, Affiliated Hosp 1, Wenzhou 325000, Zhejiang, Peoples R China.;[Lu, Junwan] Jinhua Polytech, Sch Med, Jinhua 321007, Zhejiang, Peoples R China.
通讯机构：
[Chen, Q ; Lu, B ] W;Wenzhou Med Univ, Sch Lab Med & Life Sci, Prot Qual Control & Dis Lab, Wenzhou 325035, Zhejiang, Peoples R China.;Univ South China, Hengyang Med Sch, Sch Basic Med Sci, Dept Biochem & Mol Biol, Hengyang 421001, Hunan, Peoples R China.;Wenzhou Med Univ, Dept Intens Care, Affiliated Hosp 1, Wenzhou 325000, Zhejiang, Peoples R China.
作者机构：
[Zou, Xiangman; Guo, Zifen] Univ South China, Hunan Prov Key Lab Tumor Microenvironm Respons Dr, Hunan Prov Cooperat Innovat Ctr Mol Target New Dr, Inst Pharm & Pharmacol, Hengyang 421001, Hunan, Peoples R China.;[Liu, Liya; Zou, Xiangman; Shi, Wei; Tang, Feng; Li, Wanzhen; Liu, Zhi; Huang, Wei] Chinese Acad Sci, Shanghai Inst Mat Med, Ctr Biotherapeut Discovery Res, CAS Key Lab Receptor Res,CAS Ctr Excellence Mol C, 555 Zuchongzhi Rd, Shanghai 201203, Peoples R China.;[Li, Wanzhen; Liu, Zhi] Nanjing Univ Chinese Med, Sch Chinese Mat Med, Nanjing 210023, Peoples R China.;[Huang, Wei] Univ Chinese Acad Sci, 19A Yuquan Rd, Beijing 100049, Peoples R China.;[Huang, Wei] Univ Chinese Acad Sci, Inst Adv Study, Sch Pharmaceut Sci & Technol, Hangzhou 310024, Peoples R China.
通讯机构：
[Zifen Guo] I;[Feng Tang; Wei Huang] C;CAS Key Laboratory of Receptor Research, CAS Center for Excellence in Molecular Cell Science, Center for Biotherapeutics Discovery Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Pudong, Shanghai 201203, P. R. China<&wdkj&>Institute of Pharmacy and Pharmacology, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, University of South China, Hengyang, Hunan, China<&wdkj&>CAS Key Laboratory of Receptor Research, CAS Center for Excellence in Molecular Cell Science, Center for Biotherapeutics Discovery Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, 555 Zuchongzhi Road, Pudong, Shanghai 201203, P. R. China<&wdkj&>University of Chinese Academy of Sciences, No. 19A Yuquan Road, Beijing 100049, P. R. China<&wdkj&>School of Pharmaceutical Science and Technology, Hangzhou, Institute for Advanced Study, University of Chinese Academy of Sciences, Hangzhou 310024, P. R. China
摘要：
Correction for ‘Enhanced transglycosylation activity of an Endo-F3 mutant by ligand-directed localization’ by Xiangman Zou et al., Org. Biomol. Chem., 2022, 20, 3086–3095, https://doi.org/10.1039/D2OB00030J.
作者机构：
[Jiang, Baohong] Univ South China, Affiliated Hosp 1, Hengyang Med Sch, Dept Pharm, Hengyang, Hunan, Peoples R China.;[Zhu, Hongbo; Qi, Xiaowen; Li, Yuehua; Xie, Liming; Feng, Wenjie; Wan, Zhixing] Univ South China, Affiliated Hosp 1, Hengyang Med Sch, Dept Med Oncol, Hengyang, Hunan, Peoples R China.;[He, Rongfang] Univ South China, Affiliated Hosp 1, Hengyang Med Sch, Dept Pathol, Hengyang, Hunan, Peoples R China.
通讯机构：
[Wenjie Feng; Zhixing Wan; Hongbo Zhu; Rongfang He; Liming Xie; Yuehua Li; Baohong Jiang; Xiaowen Qi] D;Department of Pathology,The First Affiliated Hospital,Hengyang Medical School,China<&wdkj&>Department of Pharmacy,The First Affiliated Hospital,Hengyang Medical School,China<&wdkj&>Department of Medical Oncology,The First Affiliated Hospital,Hengyang Medical School,China
关键词：
Introduction;Materials and Methods;Results;Discussion;Conclusion;Abstract;Data Availability;Additional Points;Ethical Approval;Consent;Disclosure;Conflicts of Interests;Authors’ Contributions;Funding Statement;Acknowledgements;Acknowledgments;Supplementary Materials;Reference;Dataset Description;Dataset Files;Abstract;Introduction;Introduction and Materials;Introduction and Methods;Materials;Materials and Methods;Methods;Results;Discussion;Results and Discussion;Discussion and Conclusion;Results and Conclusion;Conclusion;Conclusions;Data Availability;Additional Points;Ethical Approval;Consent;Disclosure;Conflicts of Interest;Authors’ Contributions;Funding Statement;Acknowledgements;Supplementary Materials;References;Appendix;Abbreviations;Preliminaries;Introduction and Preliminaries;Notation;Proof of Theorem;Proofs;Analysis of Results;Examples;Numerical Example;Applications;Numerical Simulation;Model;Model Formulation;Systematic Palaeontology;Nomenclatural Acts;Taxonomic Implications;Experimental;Synthesis;Overview;Characterization;Background;Experimental;Theories;Calculations;Model Verification;Model Implementation;Geographic location;Study Area;Geological setting;Data Collection;Field Testing;Data and Sampling;Dataset;Literature Review;Related Works;Related Work;System Model;Methods and Data;Experimental Results;Results and Analysis;Evaluation;Implementation;Case Presentation;Case Report;Search Terms;Case Description;Case Series;Background;Limitations;Additional Points;Case;Case 1;Case 2 etc.;Concern Details;Retraction Details;Copyright;Related Articles
摘要：
Background. Breast cancer is the frequent cause of disease burden related to cancer among women. It affects one in 20 women globally and up to one in eight women in high-income countries. Cuproptosis is a copper-induced modality of mitochondrial cell death that is involved in tumor proliferation and metastasis. Methods. To construct a prognostic cuproptosis-related signature, LASSO Cox regression analysis was employed. Additionally, ceRNA was developed with an aim of exploring the possible lncRNA-miRNA-mRNA regulatory axis in breast cancer. Results. The expression of FDX1, DLD, DLAT, LIAS, LIPT1, GLS MTF1, and PDHA1 was downregulated, while CDKN2A expression level was elevated in breast cancer in contrast with normal tissue. We furthermore reviewed the genetic mutation landscape of genes linked to cuproptosis in breast cancer. Prognosis analysis revealed poor OS and RFS rates in breast cancer patients with elevated levels of CDKN2A and PDHA1 and low levels of MTF1, DLD, LIPT1, and FDX1. We then constructed a cuproptosis-related signature with six genes (DKN2A, MTF1, PDHA1, DLD, LIPT1, and FDX1) for breast cancer, which predicted the OS rate with an accuracy that ranged from medium to high. Further analysis demonstrated a significant correlation between the cuproptosis-related prognostic signature and pTNM stage, MSI score, drug sensitivity, TMB score, and immune cell infiltration. Moreover, we identified the lncRNA XIST/miR-92b-3p/MTF1 regulatory axis for breast cancer. Conclusion. Multiomics approaches were used to create a cuproptosis-related signature with six genes (DKN2A, MTF1, PDHA1, DLD, LIPT1, and FDX1) for breast cancer. We discovered the lncRNA XIST/miR-92b-3p/MTF1 regulatory axis for breast cancer, which has not yet been investigated previously.
通讯机构：
[Yang Liu] H;Hunan Provincial Key Laboratory of Tumor Microenvironment Responsive Drug Research, Hunan Province Cooperative Innovation Center for Molecular Target New Drug Study, School of Pharmacology, Hengyang Medical School, University of South China, Hengyang 421001, China
摘要：
Myocardial fibrosis is a key link in the occurrence and development of diabetic cardiomyopathy. Its etiology is complex, and the effect of drugs is not good. Cardiomyocyte apoptosis is an important cause of myocardial fibrosis. The purpose of this study was to investigate the effect of gaseous signal molecule sulfur dioxide (SO(2)) on diabetic myocardial fibrosis and its internal regulatory mechanism. Masson and TUNEL staining, Western-blot, transmission electron microscopy, RT-qPCR, immunofluorescence staining, and flow cytometry were used in the study, and the interstitial collagen deposition, autophagy, apoptosis, and changes in phosphatidylinositol 3-kinase (PI3K)/AKT pathways were evaluated from in vivo and in vitro experiments. The results showed that diabetic myocardial fibrosis was accompanied by cardiomyocyte apoptosis and down-regulation of endogenous SO(2)-producing enzyme aspartate aminotransferase (AAT)(1/2). However, exogenous SO(2) donors could up-regulate AAT1/2, reduce apoptosis of cardiomyocytes induced by diabetic rats or high glucose, inhibit phosphorylation of PI3K/AKT protein, up-regulate autophagy, and reduce interstitial collagen deposition. In conclusion, the results of this study suggest that the gaseous signal molecule SO(2) can inhibit the PI3K/AKT pathway to promote cytoprotective autophagy and inhibit cardiomyocyte apoptosis to improve myocardial fibrosis in diabetic rats. The results of this study are expected to provide new targets and intervention strategies for the prevention and treatment of diabetic cardiomyopathy.
期刊：
FRONTIERS IN SURGERY,2022年9:881006 ISSN：2296-875X
通讯作者：
Cao, Z.
作者机构：
[Ying, Yidan; Cao, Zemin] Univ South China, Hengyang Med Sch, Affiliated Hosp South China 2, Dept Pharm, Hengyang, Peoples R China.;[Fei, Shuke; Qu, Xiaoyong] Univ South China, Hengyang Med Sch, Affiliated Hosp South China 2, Dept Hepatobiliary & Pancreat Surg, Hengyang, Peoples R China.;[Zeng, Zhiying] Univ South China, Hengyang Med Sch, Affiliated Hosp South China 2, Dept Anesthesiol, Hengyang, Peoples R China.
通讯机构：
[Cao, Z.] D;Department of Pharmacy, Hengyang Medical School, The Second Affiliated Hospital of South China, University of South China, Hengyang, China
